Suzetrigine: A novel pain medication with potential for the Swiss market
Suzetrigine (brand name: Journavx™) is an innovative non-opioid analgesic that was approved by the U.S. Food and Drug Administration (FDA) in January 2025 for the treatment of moderate to severe acute pain in adults. It was developed by Vertex Pharmaceuticals and represents the first new class of pain medications in more than two decades.
Mechanism of action
Suzetrigine works by selectively inhibiting the voltage-gated sodium channel NaV1.8, which is primarily expressed in peripheral pain-sensitive nerve cells. By specifically blocking this channel, suzetrigine modulates pain transmission without affecting the central nervous system, thereby avoiding the risk of dependence associated with opioid pain medications.
In clinical studies, suzetrigine showed a significant reduction in pain compared with placebo, but it was not more effective than opioids. Common side effects include itching, muscle spasms, rash, and elevated creatine kinase levels.
Although suzetrigine has already been approved in the United States, approval by the European Medicines Agency (EMA), and therefore also in Switzerland, is still pending. Given global efforts to find alternatives to opioid-containing pain medications, suzetrigine could play an important role in future pain therapy.
The introduction of suzetrigine in Switzerland would offer a new treatment option for patients with acute pain, particularly for those who are at risk of opioid dependence or for whom NSAIDs are contraindicated.
Suzetrigine represents a promising advance in pharmacological pain treatment. Its novel mechanism of action and lack of dependence potential make it an attractive alternative to existing pain medications. Future approval in Switzerland could offer patients and physicians a valuable new option for the treatment of acute pain.
However, it should be noted as a limitation that FDA approval is based on only two studies, each of which examined its use in acute, rather than chronic, pain. Due to the small number of cases, only limited conclusions can be drawn regarding its efficacy in different areas of pain therapy.